Apelin/APJ signaling in hypoxia-related diseases

Clinica Chimica Acta

Volumn 451, Issue , 2015, Pages 191-198

  He, Lu ^a   Xu, Jin ^a   Chen, Linxi ^a   Li, Lanfang ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Apelin APJ; Hypoxia related diseases; Hypoxia hypoxia inducible factor 1 alpha

Indexed keywords

APELIN; BONE MORPHOGENETIC PROTEIN; COBALT CHLORIDE; DEFEROXAMINE; DIMETHYLOXALYLGLYCINE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLYL 4 HYDROXYLASE 2; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; SUPEROXIDE DISMUTASE; TACROLIMUS; UNCLASSIFIED DRUG; APLN PROTEIN, HUMAN; APLNR PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; SIGNAL PEPTIDE;

ADIPOCYTE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HYPOXIA; HYPOXIA-INDUCED PULMONARY HYPERTENSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; MUELLER CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; ACUTE KIDNEY FAILURE; ANOXIA; BRAIN ISCHEMIA; METABOLISM; MOUTH TUMOR; OBESITY; PULMONARY HYPERTENSION; SQUAMOUS CELL CARCINOMA;

ACUTE KIDNEY INJURY; AMYOTROPHIC LATERAL SCLEROSIS; ANOXIA; BRAIN ISCHEMIA; CARCINOMA, SQUAMOUS CELL; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOUTH NEOPLASMS; OBESITY; RECEPTORS, G-PROTEIN-COUPLED; RETINOPATHY OF PREMATURITY; SIGNAL TRANSDUCTION;

EID: 84953354768     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.09.029     Document Type: Review

References (92)

1. O'Dowd B.F., Heiber M., Chan A., et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993, 136:355-360.
2. Tatemoto K., Hosoya M., Habata Y., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 1998, 251:471-476.
3. O'Carroll A.M., Selby T.L., Palkovits M., Lolait S.J. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim. Biophys. Acta 2000, 1492:72-80.
4. Berta J., Kenessey I., Dobos J., et al. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J. Thorac. Oncol. 2010, 5:1120-1129.
5. Daviaud D., Boucher J., Gesta S., et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J. 2006, 20:1528-1530.
6. Yang L., Chen L.X. Regulatory function of apelin/APJ system on multiple systems. International journal of pathology and clinical medicine 2011, 31:42-48.
7. Wu D., He L., Chen L. Apelin/APJ system: a promising therapy target for hypertension. Mol. Biol. Rep. 2014, 41:6691-6703.
8. Xie F., Lv D., Chen L. ELABELA: a novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor. Acta Biochim. Biophys. Sin. 2014, 46:620-622.
9. Cao J., Li H., Chen L. Targeting drugs to APJ receptor: the prospect of treatment of hypertension and other cardiovascular diseases. Curr. Drug Targets 2015, 16:148-155.
10. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 1997, 272:19253-19260.
11. Vengellur A., Woods B.G., Ryan H.E., Johnson R.S., LaPres J.J. Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts. Gene Expr. 2003, 11:181-197.
12. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. Journal of applied physiology (Bethesda, Md: 1985) 2000, 88:1474-1480.
13. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
14. Sen Banerjee S., Thirunavukkarasu M., Tipu Rishi M., Sanchez J.A., Maulik N., Maulik G. HIF-prolyl hydroxylases and cardiovascular diseases. Toxicol. Mech. Methods 2012, 22:347-358.
15. Eyries M., Siegfried G., Ciumas M., et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ. Res. 2008, 103:432-440.
16. Beck I., Weinmann R., Caro J. Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 1993, 82:704-711.
17. Goldberg M.A., Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 1994, 269:4355-4359.
18. Maxwell P.H., Ratcliffe P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 2002, 13:29-37.
19. Casals G., Fernandez-Varo G., Melgar-Lesmes P., et al. Factors involved in extracellular matrix turnover in human derived cardiomyocytes. Cell. Physiol. Biochem. 2013, 32:1125-1136.
20. Ronkainen V.P., Ronkainen J.J., Hanninen S.L., et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007, 21:1821-1830.
21. Kong H.L., Li Z.Q., Zhao S.M., et al. Apelin-APJ effects of ginsenoside-Rb1 depending on hypoxia-induced factor 1alpha in hypoxia neonatal cardiomyocytes. Chin. J. Integr. Med. 2015, 21:139-146.
22. Cox C.M., D'Agostino S.L., Miller M.K., Heimark R.L., Krieg P.A. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev. Biol. 2006, 296:177-189.
23. Sheikh A.Y., Chun H.J., Glassford A.J., et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H88-H98.
24. Zhang J., Liu Q., Hu X., et al. Apelin/APJ signaling promotes hypoxiainduced proliferation of endothelial progenitor cells via phosphoinositide3 kinase/Akt signaling. Mol. Med. Rep. 2015, 12:3829-3834.
25. Glassford A.J., Yue P., Sheikh A.Y., et al. HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1590-E1596.
26. Geiger K., Muendlein A., Stark N., et al. Hypoxia induces apelin expression in human adipocytes. Horm. Metab. Res. 2011, 43:380-385.
27. Kunduzova O., Alet N., Delesque-Touchard N., et al. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J. 2008, 22:4146-4153.
28. Sorli S.C., Le Gonidec S., Knibiehler B., Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene 2007, 26:7692-7699.
29. Heo K., Kim Y.H., Sung H.J., et al. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol. 2012, 48:500-506.
30. Masri B., van den Berghe L., Sorli C., Knibiehler B., Audigier Y. Apelin signalisation and vascular physiopathology. J. Soc. Biol. 2009, 203:171-179.
31. Han S., Wang G., Qi X., Lee H.M., Englander E.W., Greeley G.H. A possible role for hypoxia-induced apelin expression in enteric cell proliferation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294:R1832-R1839.
32. Wang X.L., Tao Y., Lu Q., Jiang Y.R. Apelin supports primary rat retinal Muller cells under chemical hypoxia and glucose deprivation. Peptides 2012, 33:298-306.
33. Lu Q., Jiang Y.R., Qian J., Tao Y. Apelin-13 regulates proliferation, migration and survival of retinal Muller cells under hypoxia. Diabetes Res. Clin. Pract. 2013, 99:158-167.
34. Andersen C.U., Markvardsen L.H., Hilberg O., Simonsen U. Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension. Respir. Med. 2009, 103:1663-1671.
35. Melgar-Lesmes P., Pauta M., Reichenbach V., et al. Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut 2011, 60:1404-1411.
36. Kerkela R., Karsikas S., Szabo Z., et al. Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection. Mol. Cell. Biol. 2013, 33:3321-3329.
37. Li L., Li L., Zhang Z., Jiang Z. Hypoxia promotes bone marrow-derived mesenchymal stem cell proliferation through apelin/APJ/autophagy pathway. Acta Biochim. Biophys. Sin. (Shanghai) 2015, 47:362-367.
38. Poirier O., Ciumas M., Eyries M., Montagne K., Nadaud S., Soubrier F. Inhibition of apelin expression by BMP signaling in endothelial cells. Am. J. Physiol. Cell Physiol. 2012, 303:C1139-C1145.
39. Yang F., Bai Y., Jiang Y. Effects of apelin on RAW264.7 cells under both normal and hypoxic conditions. Peptides 2015, 69:133-143.
40. Loewen N., Chen J., Dudley V.J., Sarthy V.P., Mathura J.R. Genomic response of hypoxic Muller cells involves the very low density lipoprotein receptor as part of an angiogenic network. Exp. Eye Res. 2009, 88:928-937.
41. Kasai A., Ishimaru Y., Kinjo T., et al. Apelin is a crucial factor for hypoxia-induced retinal angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2182-2187.
42. Galie N., Palazzini M., Manes A. Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. Eur. Respir. J. 2010, 36:986-990.
43. Noureddine H., Gary-Bobo G., Alifano M., et al. Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. Circ. Res. 2011, 109:543-553.
44. Haddad F., Peterson T., Fuh E., et al. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ. Heart Fail. 2011, 4:692-699.
45. Kawamata Y., Habata Y., Fukusumi S., et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim. Biophys. Acta 2001, 1538:162-171.
46. Fan X.F., Wang Q., Mao S.Z., et al. Protective and therapeutic effect of apelin on chronic hypoxic pulmonary hypertension in rats 2010, 26:9-12.
47. Chandra S.M., Razavi H., Kim J., et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 2011, 31:814-820.
48. Chen S., Xue F., Jin H.L., et al. Effect of swimming exercise on the expression of apelin and its receptor in pulmonary tissues of rats with hypoxic pulmonary hypertension. Chin. J. Appl. Physiol. 2012, 28:5-8.
49. Spiekerkoetter E., Tian X., Cai J., et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J. Clin. Invest. 2013, 123:3600-3613.
50. Mao S.Z., Hong L., Hu L.G., et al. Effect of apelin on hypoxic pulmonary hypertension in rats: role of the NO pathway. Sheng li xue bao: Acta physiologica Sinica 2009, 61:480-484.
51. Morrell N.W., Adnot S., Archer S.L., et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54:S20-S31.
52. Zhang H., Gong Y., Wang Z., et al. Apelin inhibits the proliferation and migration of rat PASMCs via the activation of PI3K/Akt/mTOR signal and the inhibition of autophagy under hypoxia. J. Cell. Mol. Med. 2014, 18:542-553.
53. Li F., Li L.F., Qin X.P., et al. The study of vascular smooth muscle cells proliferation stimulated by apelin- 13. Chin. Pharmacol. Bull. 2007, 23:943-953.
54. Feng L., Lan F.L., Xu P.Q., et al. Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front. Biosci. 2008, 13:3786-3792.
55. Liu C., Su T., Li F., et al. PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42:396-402.
56. Li L., Li L., Xie F., et al. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim. Biophys. Sin. (Shanghai) 2013, 45:875-881.
57. Li L.F., Li F., et al. NOX4-derived reactive oxygen species drive apelin-13-induced vascular smooth muscle cell proliferation via the ERK pathway. Int. J. Pept. Res. Ther. 2011, 17:307-315.
58. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart 2007, 93:1137-1146.
59. Zeng X.J., Zhang L.K., Wang H.X., Lu L.Q., Ma L.Q., Tang C.S. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009, 30:1144-1152.
60. Lan F.L., Heng Z., Xu W.H., Xiao C.H., Jian-Xiong C. Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction. PLoS One 2013, 8:1-11.
61. Pisarenko O., Shulzhenko V., Studneva I., et al. Structural apelin analogues: mitochondrial ROS inhibition and cardiometabolic protection in myocardial ischaemia reperfusion injury. Br. J. Pharmacol. 2015, 172:2933-2945.
62. Wang W., McKinnie S.M., Patel V.B., et al. Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues. J. Am. Heart Assoc. 2013, 2.
63. Gu Q., Zhai L., Feng X., et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem. Int. 2013, 63:535-540.
64. Kademani D. Oral cancer. Mayo Clin. Proc. Mayo Clin. 2007, 82:878-887.
65. Sano D., Myers J.N. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 2007, 26:645-662.
66. Carvalho A.L., Nishimoto I.N., Califano J.A., Kowalski L.P. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int. J. Cancer J. Int. Cancer 2005, 114:806-816.
67. Van Meir E. Hypoxia-mediated selection of cells with diminished apoptotic potential to solid tumours. Neurosurgery 1996, 39:878-879.
68. Kalin R.E., Kretz M.P., Meyer A.M., Kispert A., Heppner F.L., Brandli A.W. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev. Biol. 2007, 305:599-614.
69. Yang L., Su T., Lv D., et al. ERK1/2 mediates lung adenocarcinoma cell proliferation and autophagy induced by apelin-13. Acta Biochim. Biophys. Sin. (Shanghai) 2014, 46:100-111.
70. Chen J., Smith L.E. Retinopathy of prematurity. Angiogenesis 2007, 10:133-140.
71. Vessey K.A., Wilkinson-Berka J.L., Fletcher E.L. Characterization of retinal function and glial cell response in a mouse model of oxygen-induced retinopathy. J. Comp. Neurol. 2011, 519:506-527.
72. Claxton S., Fruttiger M. Oxygen modifies artery differentiation and network morphogenesis in the retinal vasculature. Dev. Dyn. 2005, 233:822-828.
73. Cekmez F., Pirgon O., Aydemir G., et al. Correlation between cord blood apelin and IGF-1 levels in retinopathy of prematurity. Biomark. Med 2012, 6:821-825.
74. Zhang Y., Jiang Y.R., Lu Q., Yin H., Tao Y. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab. Retina 2013, 33:613-620.
75. Cavallaro G., Filippi L., Bagnoli P., et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol. (Copenh) 2014, 92:2-20.
76. Kasai A., Shintani N., Oda M., et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem. Biophys. Res. Commun. 2004, 325:395-400.
77. Kasai A., Shintani N., Kato H., et al. Retardation of retinal vascular development in apelin-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1717-1722.
78. Saint-Geniez M., Masri B., Malecaze F., Knibiehler B., Audigier Y. Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech. Dev. 2002, 110:183-186.
79. Vermeiren C., Hemptinne I., Vanhoutte N., Tilleux S., Maloteaux J.M., Hermans E. Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. J. Neurochem. 2006, 96:719-731.
80. Oosthuyse B., Moons L., Storkebaum E., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001, 28:131-138.
81. Kasai A., Kinjo T., Ishihara R., et al. Apelin deficiency accelerates the progression of amyotrophic lateral sclerosis. PLoS One 2011, 6.
82. Chen H., Wan D., Wang L., et al. Apelin protects against acute renal injury by inhibiting TGF-beta1. Biochim. Biophys. Acta 2015, 6. (00064-00062).
83. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol. Rev. 2013, 93:1-21.
84. Boydens C., Maenhaut N., Pauwels B., Decaluwe K., Van de Voorde J. Adipose tissue as regulator of vascular tone. Curr. Hypertens. Rep. 2012, 14:270-278.
85. Rocha S. Gene regulation under low oxygen: holding your breath for transcription. Trends Biochem. Sci. 2007, 32:389-397.
86. Michailidou Z., Turban S., Miller E., et al. Increased angiogenesis protects against adipose hypoxia and fibrosis in metabolic disease-resistant 11beta-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice. J. Biol. Chem. 2012, 287:4188-4197.
87. Rask E., Olsson T., Soderberg S., et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 2001, 86:1418-1421.
88. Zhou N., Fang J., Acheampong E., Mukhtar M., Pomerantz R.J. Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology 2003, 312:196-203.
89. Maloney P.R., Khan P., Hedrick M., et al. Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg. Med. Chem. Lett. 2012, 22:6656-6660.
90. Lee D.K., Saldivia V.R., Nguyen T., Cheng R., George S.R., O'Dowd B.F. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005, 146:231-236.
91. Brame A.L., Maguire J.J., Yang P., et al. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension 2015, 65:834-840.
92. Iturrioz X., Alvear-Perez R., De Mota N., et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J. 2010, 24:1506-1517.